

(A) Drawing of sensory deficit; (B) MRI showing clot in the left vertebral artery and infarcts in the lateral medulla and cerebellum (arrows), (C) arrowhead pointing at the occlusion of the left vertebral artery.

distribution of the lateral branches of the left posterior inferior cerebellar artery.[4] There was a crescent sign involving the left vertebral artery from the skull base to the basilar artery suggesting vertebral artery dissection (figure).

Four types of lateral medullary infarct are recognised: small midlateral infarct, inferolateral infarct, and a large inferodorsolateral and dorsolateral infarct. The topography of the lesion in our patient corresponds to inferolateral medullary infarct.[3] The patients with inferolateral infarcts and midlateral infarcts in the literature were not recognised to have cerebellar infarct and magnetic resonance angiography in those patients was normal by contrast with our patient.[3] The partial lesion of the lateral spinothalamic tract in our patient involved only the far lateral fibres containing sacral afferents leading to sparing of the arm and face. The spinal trigeminal nucleus and tract, which contain afferents for the face ipsilateral to the lesion, reside dorsolaterally and the crossed ventral trigeminothalamic tract, which contains afferents for the contralateral face, resides medial to the lateral spinothalamic tract. Lesion of the spinocerebellar tract involving only the sacral fibres explains the presence of severe gait ataxia but no upper limb ataxia.[3] The counterclockwise rotatory nystagmus is likely due to imbalance of projections from the anterior and posterior semicircular canals and the otolith receptor.[5]

A sensory level to the trunk may point to a lateral brainstem lesion in the presence of other features suggesting brainstem disease. In our patient these signs were transient and sensory loss predominated. This new pattern of sensory loss should be recognised as symptomatic of lateral medullary infarction in addition to other sensory variants.[1–3]

THANH G PHAN
EELCO F M WIJDICKS
Department of Neurology, Mayo Medical Center and Foundation, Rochester, MN, USA

Correspondence to: Dr E F M Wijdicks, Mayo Clinic, Department of Neurology (W8A), Correspondence to: E F M Wijdicks, MD, 200 First Street SW, Rochester, MN 55905, USA. Telephone 001 507 284 5443; fax 001 507 284 4795; email wijde@mayo.edu

1 Vuadens P, Bogousslavsky J. Face-arm-trunk-leg sensory loss limited to the contralateral side in lateral medullary infarction: a new variant. *J Neurol Neurosurg Psychiatry* 1998;**65**:255–7.
2 Masumoto S, Okuda B, Imai T, *et al*. A sensory level on the trunk in lower lateral brainstem lesions. *Neurology* 1988;**38**:1515–9.
3 Vuilleumier P, Bogousslavsky J, Regli F. Infarction of the lower brainstem. Clinical, aetiological and MRI-topographical correlations. *Brain* 1995;**118**:1013–25.
4 Tatu L, Moulin T, Bogousslavsky J, *et al*. Arterial territories of human brain: brainstem and cerebellum. *Neurology* 1996;**47**:1125–35.
5 Morrow M, Sharpe JA. Torsional nystagmus in the lateral medullary syndrome. *Ann Neurol* 1988;**24**:390–8. **125**:194–7.

Sudden unexpected death: a rare event in a large community based prospective cohort with newly diagnosed epilepsy and high remission rates

It is now accepted that mortality in epilepsy is significantly increased, with standard mortality ratios raised twofold or threefold. Early deaths are usually attributable to the underlying cause of epilepsy and mortality in chronic cases is commonly due to the epilepsy itself.[1] Of the deaths that are directly related to epilepsy, the commonest category is sudden unexpected death in epilepsy (SUDEP). This is widely defined as a sudden unexpected, non-traumatic and non-drowning death in a person with epilepsy with or without evidence of a seizure and excluding documented status epilepticus in which postmortem examination does not disclose a cause of death. Less common causes are status epilepticus, accidents due to seizures, drowning, and aspiration. The National General Practice Study of Epilepsy (NGPSE) is a prospective, population based, observational study of 792 patients with newly diagnosed epilepsy (564 definite cases and 228 probable cases)[2] followed up for 8000 patient-years and has provided valuable insights into the prognosis and mortality of epilepsy. Fifty per cent of the definite cases were between the ages of 15 and 59 years—encompassing the age band in which the phenomenon of SUDEP is most commonly found. The overall standardised mortality ratio among patients with definite epilepsy in this cohort was 3.0 (95% confidence interval (95% CI) 2.5–3.7).[1]

The true incidence of SUDEP is not precisely known. Studies have varied in their methodology and study populations have ranged from those in death certificates and coroners' registers (more community based) to epilepsy surgery cohorts and institutionalised patients (patients with chronic epilepsy).[3] Figures derived from community based prospective studies indicate numbers of up to 1:1100.[4] Patients with chronic epilepsy seem to have a much higher incidence of SUDEP and a tertiary clinic based population with chronic epilepsy in the United Kingdom had an estimated incidence of 1:200 patients.[5] This is in some contrast with the two SUDEP deaths in 5000 patient years reported by the MRC Anti-epileptic Withdrawal Study Group for patients in remission from epilepsy.[6]

We report the first sudden unexpected death in epilepsy in the NGPSE. A 42 year old man known to have poorly controlled idiopathic generalised epilepsy treated with phenytoin and sodium valproate, was found dead in bed, having been well in the hours and days preceding death. He was known to misuse alcohol and was questionably compliant with medication, both factors thought to increase the risk of sudden death. A necropsy did not disclose any relevant pathology—consistent with the definition of SUDEP.

Mortality has been studied in detail in this large cohort[1] and it was only in the 13th year of follow up (8000 patient-years) that the first SUDEP was reported. This could falsely give the impression that SUDEP is a rare occurrence and it must be borne in mind that in large community based cohorts such as the NGPSE, most patients enter remission from seizures and it is the patients who continue to have epilepsy that are most at risk from sudden death. Indeed in this cohort, the number of patients who still have active epilepsy, using International League Against Epilepsy

criteria for remission (no seizures for 5 years or more with or without medication) and on follow up are 111 from an original 792 who had definite or probable epilepsy. On its own, therefore, it does not provide a true indication of the incidence of SUDEP but it is nevertheless an interesting finding on the prognosis of epilepsy in a large, community based cohort.

Financial support and sources of funding for the NGPSE were the National Hospital for Neurology and Neurosurgery, Brain Research Trust, and the National Society for Epilepsy.

S D LHATOO
Y LANGAN
B K MACDONALD
S ZEIDAN
J W A S SANDER
Epilepsy Research Group and Neuroepidemiology Unit, Institute of Neurology and the National Hospital for Neurology and Neurosurgery, 33 Queen Square, London, UK

Correspondence to: Dr S D Lhatoo, Epilepsy Research Group and Neuroepidemiology Unit, Institute of Neurology and the National Hospital for Neurology and Neurosurgery, 33 Queen Square, London WC1N 3BG, UK

1 Cockerell OC, Johnson AL, Sander JWAS, *et al*. Mortality from epilepsy. *Lancet* 1994;**344**:918–21.
2 Hart YM, Sander JWAS, Shorvon SD. National general practice study of epilepsy and epileptic seizures: objectives and study methodology of the largest reported prospective cohort study of epilepsy. *Neuroepidemiology* 1989;**8**:221–7.
3 O'Donoghue MF, Sander JWAS. The mortality associated with epilepsy, with particular reference to sudden unexpected death: a review. *Epilepsia* 1997;**38**:S15–19
4 Leestma JE, Walczak T, Hughes JR, *et al*. A prospective study on sudden unexpected death in epilepsy. *Ann Neurol* 1989;**26**:195–203.
5 Nashef L, Sander JWAS, Fish DR, *et al*. Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre. *J Neurol Neurosurg Psychiatry* 1995;**58**:462–4.
6 Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. *Lancet* 1991;**337**:1175–80.

Opportunities for improving the quality of care in malignant cerebral glioma

There is scope for improving the services offered to patients with malignant glioma. Clinical audit has highlighted several important issues including some variation in the management of patients aged over 60,[1] delays in beginning treatment, and problems with communication between different departments involved in patient care.[2] A multidisciplinary Working Group, funded by the NHS Executive, recently developed evidence based guidelines for the management of these patients by surgery, radiotherapy, and chemotherapy. The group also considered the views of patients and their relatives about follow up and psychosocial aspects of care.[3]

We have derived a package of audit measures from these guidelines that allow treatment centres to assess the care that they provide.[4] Proformas within the package cover various topics—for example, technical aspects of treatment, breaking the news of the diagnosis, the support of patients and relatives, and palliative care while in the community. Information is drawn from case records, feedback from patients, relatives and general practitioners, and review of the policy a centre has already developed.

We piloted the proforma by reviewing the case records of 60 patients diagnosed at two treatment centres in London between 1992 and 1994. The table shows some results using one proforma which covers breaking the news of the diagnosis. We found, for example, that overall most case records (67%,40/60) did not record what the patient and their relative had initially been told about the prognosis. However, there did seem to be a difference between centres. At one, clinicians rarely recorded what they had said to patients and relatives whereas at the other this was recorded in just over 50% of cases. Patients at one centre were also more likely to be seen subsequently by counselling or palliative care services. Neither centre had the benefit of a dedicated specialist nurse in neuro-oncology.

The lack of a record does not, of course, mean that the diagnosis and prognosis were not actually discussed in some depth with the patient and relative. However, clearly it is likely to be helpful for others involved in the care of the patient to have sight of such a record. It is also possibly relevant that an earlier study found that only a quarter of a sample of 75 patients drawn from different centres seemed to be fully aware of the likely prognosis for their disease as they began treatment.[4]

The aim of the guidelines developed by the Working Group has been to suggest methods which will help decision making in general terms rather than provide firm guidance on how particular patients should be treated. For example, an initial assessment of patient disability is recommended. Ten of the 60 case records we audited included some assessment of disability, but none formally recorded the patient's performance status, an important prognostic factor, using either the WHO clinical performance status or the Karnofsky score.

The current review of cancer services after the Calman-Hine report[5] represents an opportunity for the development of neuro-oncology services in Great Britain. A few centres have made progress towards the ideal of neuro-oncology clinics with specialist nurse support and well developed links with rehabilitation and palliative care. The guidelines and audit measures developed by the Working Group will need to be adapted for local circumstances, but treatment centres and purchasers may find them a useful tool in assessing and developing their services.

ELIZABETH DAVIES
MAUREEN BANNON
Research Unit, Royal College of Physicians, 11 St Andrew's Place, Regents Park, London NW1 4LE, UK

Record of explanation given to patients and relatives after the diagnosis and referral for counselling or palliative care services. Figures are numbers (percentages of patients)

	Centre A n=30 (%)	*Centre B n=30 (%)*
Diagnosis explained to patient	8 (27)	6 (20)
Prognosis explained to patient	17 (57)	3 (10)
Prognosis explained to relative	15 (50)	8 (27)
Referral to counselling or palliative care service	12 (40)	2 (7)

Correspondence to: Dr Elizabeth Davies, Research Unit, Royal College of Physicians, 11 St Andrew's Place, Regents Park, London NW1 4LE, UK.

1 Whittle IR, Denholm SW, Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. *Surg Neurol* 1991;**2**:106–11.
2 Grant R, Collie D, Gregor A, *et al*. Referral pattern and management of patients with malignant brain tumours in South East Scotland. *Health Bull* 1996;**54**:212–22.
3 Davies E, Hopkins A. On behalf of a working group. Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. *Br J Neurosurg* 1997;**11**: 318–30.
4 Davies E, Hopkins A, eds. *Improving care for patients with malignant cerebral glioma*. London: RCP Publications, 1997.
5 Calman-Hine Report. Expert Advisory Group on Cancer. A policy framework for commissioning cancer services. London: Department of Health, 1995.

CORRESPONDENCE

MRI in vertebral artery dissection

In a recent report, Auer *et al* described the clinical and imaging findings in 19 cases of extracranial vertebral artery dissection retrospectively.[1] We make the following comments.

Firstly, the authors described the "sensitivity" and "specificity" of digital subtraction angiography (DSA), magnetic resonance imaging/angiography (MRI/A), and duplex sonography for diagnosing extracranial vertebral artery dissection.[1] These figures were based on the percentage of probable and definite features among the 19 patients. Nevertheless, sensitivity of a test is the number of cases with true positive results divided by the total number of positive results (including both true and false positives), and specificity is the number of cases with true negative results over the sum of true and false negatives. The authors misquoted the terms "sensitivity" and "specificity" in their report, as the diagnostic criteria of the various tests have not been applied to a control group to disclose the false positive cases and true negative cases. Secondly, the criteria for case inclusion were not defined. Apparently, extracranial vertebral artery dissection was diagnosed by either radiological features on MRI/A (which may be "pathognomonic" or "suggestive") in the appropriate clinical context or confirmatory radiological features on DSA (which may be "specific" or "indirect"). The accuracy and usefulness of DSA, MRI/A, and duplex sonography cannot be compared directly, as no single "gold standard" diagnostic method was used and because results of the present study simply reflected the proportion of cases diagnosed by the authors.

Dissection of neck arteries was thought to be an uncommon cause of ischaemic stroke. The true incidence of this condition remains unknown as angiography is not performed in every patient during the acute or subacute phase. Younger patients are more likely to undergo early angiography when there is a history of recent neck trauma[2] or pain, or when no other causes of stroke are apparent. This selection bias may underestimate the